Chemoprevention of colorectal cancer: An update

Techniques in Coloproctology

Volumn 8, Issue SUPPL. 2, 2004, Pages

  Serrano, D ^a   Lazzeroni, M ^a   Decensi, A ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b GALLIERA HOSPITAL   (Italy)

Author keywords

Chemoprevention; Clinical trial; Colorectal neoplasms

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; ESTROGEN; GESTAGEN; NONSTEROID ANTIINFLAMMATORY AGENT; VITAMIN D;

CALCIUM INTAKE; CANCER PREVENTION; CANCER THERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; DIETARY INTAKE; DRUG EFFICACY; DRUG SAFETY; HORMONE SUBSTITUTION; HUMAN; NUTRIENT; REVIEW; SIDE EFFECT; STROKE; VITAMIN INTAKE;

CHEMOPREVENTION; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS;

EID: 13444282283     PISSN: 11236337     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10151-004-0170-5     Document Type: Review

References (44)

1. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O (1996) Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348:1467-1471
2. Hardcastle JD, Chamberlain JO, Robinson MH et al (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348:1472-1477
3. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS (1992) A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 326:653-657
4. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM (1992) Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 84:1572-1575
5. Vernon SW (1997) Participation in colorectal cancer screening: a review. J Natl Cancer Inst 89:1406-1422
6. Garcia RL, Huerta-Alvarez C (2000) Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 11:376-381
7. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252-266
8. Giardiello FM, Hamilton SR, Krush AJ et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316
9. Steinbach G, Lynch PM, Phillips RK et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952
10. Giovannucci E, Egan KM, Hunter DJ et al (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609-614
11. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH (1998) Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 128:713-720
12. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH (1993) Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85:1220-1224
13. Baron JA, Cole BF, Sandler RS et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899
14. Sandler RS, Halabi S, Baron JA et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883-890
15. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A (2003) Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124:600-607
16. Williams JL, Nath N, Chen J et al (2003) Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res 63:7613-7618
17. Fiorucci S, Santucci E, Wallace JE et al (2003) Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA 100:10937-10941
18. Alberts DS, Martinez ME, Roe DJ et al (2000) Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 342:1156-1162
19. Schatzkin A, Lanza E, Corle D et al (2000) Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 342:1149-1155
20. Lamprecht SA, Lipkin M (2003) Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 3:601-614
21. Baron JA, Beach M, Mandel JS et al (1999) Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 340:101-107
22. Wallace K, Baron JA, Cole BF et al (2004) Effect of calcium supplementation on the risk of large bowel polyps. J Natl Cancer Inst 96:921-925
23. Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U, Faivre J (2000) Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 356:1300-1306
24. Cho E, Smith-Warner SA, Spiegelman D et al (2004) Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst 96:1015-1022
25. Grau MV, Baron JA, Sandler RS et al (2003) Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 95:1765-1771
26. Giovannucci E, Stampfer MJ, Colditz GA et al (1998) Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med 129:517-524
27. Fuchs CS, Willett WC, Colditz GA et al (2002) The influence of folate and multivitamin use on the familial risk of colon cancer in women. Cancer Epidemiol Biomarkers Prev 11:227-234
28. Konings EJ, Goldbohm RA, Brants HA, Saris WH, van den Brandt PA (2002) Intake of dietary folate vitamers and risk of colorectal carcinoma: results from The Netherlands Cohort Study. Cancer 95:1421-1433
29. Kawamori T, Lubet R, Steele VE et al (1999) Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 59:597-601
30. Spector D, Anthony M, Alexander D, Arab L (2003) Soy consumption and colorectal cancer. Nutr Cancer 47:1-12
31. Bushman JL (1998) Green tea and cancer in humans: a review of the literature. Nutr Cancer 31:151-159
32. Murakami A, Takahashi D, Kinoshita T et al (2002) Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the alpha,beta-unsaturated carbonyl group is a prerequisite. Carcinogenesis 23:795-802
33. Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106:574-582
34. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW, Jr (1995) Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 87:517-523
35. The Boston Collaborative Drug Surveillance Program, Boston University Medical Center (1974) Surgically confirmed gall-bladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 290:15-19
36. Bennion LJ, Ginsberg RL, Gernick MB, Bennett PH (1976) Effects of oral contraceptives on the gallbladder bile of normal women. N Engl J Med 294:189-192
37. Singh S, Paraskeva C, Gallimore PH, Sheppard MC, Langman MJ (1994) Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anticancer Res 14:1037-1041
38. Schwartz B, Smirnoff P, Shany S, Liel Y (2000) Estrogen controls expression and bioresponse of 1,25-dihydroxyvitamin D receptors in the rat colon. Mol Cell Biochem 203:87-93
39. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
40. Anderson GL, Limacher M, Assaf AR et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712
41. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al (2004) Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350:991-1004
42. Newcomb PA, Storer BE (1995) Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 87:1067-1071
43. Grady D, Wenger NK, Herrington D et al (2000) Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 132:689-696
44. Slattery ML, Ballard-Barbash R, Edwards S, Caan BJ, Potter JD (2003) Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States). Cancer Causes Control 14:75-84